- Datum04.12.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalterstock3
Redhill Biopharma Ltd. Reg.Shares(Spon.ADRs)10 IL-,01 Chart
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnenRedhill Biopharma Ltd. Reg.Shares(Spon.ADRs)10 IL-,01 Realtime-Kurs
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
Nasdaq | VK | |||||
Nasdaq Basic | VK | |||||
Cboe BZX | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu Redhill Biopharma Ltd. Reg.Shares(Spon.ADRs)10 IL-,01
Webinar zu Redhill Biopharma Ltd. Reg.Shares(Spon.ADRs)10 IL-,01
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)6,345-82,000
- Jahrestief / Hoch ($)6,345-38,500
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Redhill Biopharma Ltd. Reg.Shares(Spon.ADRs)10 IL-,01
Termine von Redhill Biopharma Ltd. Reg.Shares(Spon.ADRs)10 IL-,01
Beschreibung
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.